The European Commission granted marketing authorization to Akantior for the treatment of Acanthamoeba keratitis, according to a press release from Avanzanite Bioscience.
The decision was backed by positive results from the phase 3 pivotal Orphan Drug for Acanthamoeba Keratitis (ODAK) trial, which included 135 patients. Of these patients, 84.8% were cured of Acanthamoeba keratitis (AK) after treatment with Akantior (polyhexanide, Avanzanite Bioscience). In addition, 66.7% of patients achieved full vision restoration without the need for optical cornea transplants.
According to the release, the